Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma.
[esophageal squamous cell carcinoma]
This
retrospective
analysis
evaluates
the
clinical
efficacy
and
toxicity
of
second
-line
docetaxel-based
chemotherapy
after
failure
of
fluorouracil-based
first
-line
treatment
for
advanced
esophageal
squamous
cell
carcinoma
(
ESCC
)
.
We
retrospectively
reviewed
patients
who
had
received
second
-line
docetaxel-based
chemotherapy
for
advanced
ESCC
in
Zhejiang
Cancer
Hospital
between
January
2008
and
December
2011
.
Survival
curves
were
plotted
using
the
Kaplan-
Meier
method
.
The
Cox
proportional
hazard
model
was
used
for
multivariate
analysis
.
Eighty
-
five
patients
received
docetaxel-based
second
-line
chemotherapy
after
the
failure
of
first
-line
fluorouracil-based
treatment
.
Forty
-
four
patients
received
docetaxel-platinum
chemotherapy
,
and
41
received
docetaxel
single
-
agent
treatment
.
The
progression-free
survival
(
PFS
)
and
overall
survival
(
OS
)
were
3
.
5
and
5
.
5
months
in
all
of
the
patients
,
respectively
.
There
were
no
statistically
significant
differences
in
PFS
and
OS
between
docetaxel-platinum
and
docetaxel
single
-
agent
chemotherapy
groups
(
P-
value
0
.
38
and
0
.
64
,
respectively
)
.
Response
to
first
-line
chemotherapy
was
a
favorable
prognostic
factor
for
PFS
in
uni-
and
multivariate
analyses
(
P-
value
0
.
005
and
0
.
028
,
respectively
)
.
Patients
with
docetaxel-based
second
-line
treatment
obtained
a
moderate
PFS
advantage
in
advanced
ESCC
.
Response
to
first
-line
chemotherapy
was
a
favorable
prognostic
factor
for
PFS
of
second
-line
chemotherapy
in
advanced
ESCC
.
Diseases
Validation
Diseases presenting
"squamous cell carcinoma"
symptom
carcinoma of the gallbladder
child syndrome
dystrophic epidermolysis bullosa
epidermolysis bullosa simplex
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
junctional epidermolysis bullosa
kallmann syndrome
kindler syndrome
liposarcoma
monosomy 21
oculocutaneous albinism
oral submucous fibrosis
papillon-lefèvre syndrome
This symptom has already been validated